/IRWD
IRWD Stock - Ironwood Pharmaceuticals, Inc.
Healthcare|Drug Manufacturers - Specialty & GenericNASDAQ
$3.13-3.99%
$0.13 (-3.99%) • Dec 19
87
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.100
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).93
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+21.4%upside
Target: $3.80
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for IRWD
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$3.10 – $3.16
TARGET (TP)$3.80
STOP LOSS$2.88
RISK/REWARD1:2.7
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.18
52W High$4.78
52W Low$0.53
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $351.41M | $442.74M | $410.60M | $413.75M | $389.52M |
| Gross Profit | $343.86M | $436.59M | $409.18M | $343.35M | $386.39M |
| Gross Margin | 97.9% | 98.6% | 99.7% | 83.0% | 99.2% |
| Operating Income | $93.12M | $-945,430,000 | $250.34M | $232.26M | $142.94M |
| Net Income | $880,000 | $-1,002,239,000 | $175.06M | $528.45M | $106.18M |
| Net Margin | 0.3% | -226.4% | 42.6% | 127.7% | 27.3% |
| EPS | $0.01 | $-6.45 | $1.13 | $3.26 | $0.67 |
Company Overview
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and CNP-104, an immune nanoparticle for the treatment of biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
3
50%
Hold / Neutral
3
50%
Sell / Underperform
0%
Analyst Consensus🟡 Mixed
3 Bullish3 Neutral/Bearish
Price Targets
$16
Average Target
↑ 395.2% Upside
Now
$4
Low
$16
Average
$22
High
Based on 8 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| April 15th 2025 | Wells Fargo | Downgrade | Equal Weight | - |
| April 15th 2025 | Jefferies | Downgrade | Hold | - |
| April 14th 2025 | Citizens JMP | Downgrade | Market Perform | - |
| September 9th 2024 | Leerink Partners | Initiation | Market Perform | $5 |
| August 8th 2024 | CapitalOne | Downgrade | Equal Weight | $4← $12 |
| January 17th 2024 | Craig Hallum | Initiation | Buy | $21 |
| December 14th 2023 | Wells Fargo | Initiation | Overweight | $20 |
| November 9th 2023 | Jefferies | Initiation | Buy | $21 |
| September 28th 2023 | JMP Securities | Initiation | Mkt Outperform | $22 |
| September 2nd 2022 | CapitalOne | Initiation | Overweight | $15 |
| April 22nd 2022 | Piper Sandler | Initiation | Overweight | $16 |
Earnings History & Surprises
IRWDBeat Rate
39%
Last 18 quarters
Avg Surprise
+15.7%
EPS vs Estimate
Beats / Misses
7/10
1 met exactly
Latest EPS
$0.24
Q4 2025
EPS Surprise History
Q1 24
-104.8%
$-0.01vs$0.21
Q2 24
-111.1%
$-0.02vs$0.18
Q3 24
-103.6%
$-0.01vs$0.15
Q4 24
-75.0%
$0.02vs$0.08
Q1 25
-80.0%
$0.02vs$0.10
Q2 25
-180.0%
$-0.14vs$-0.05
Q3 25
+800.0%
$0.14vs$-0.02
Q4 25
+166.7%
$0.24vs$0.09
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 5, 2026 | — | — | — | — |
Q1 2026 | Feb 26, 2026 | $0.02 | — | — | — |
Q4 2025 | Nov 10, 2025 | $0.09 | $0.24 | +166.7% | ✓ BEAT |
Q3 2025 | Aug 7, 2025 | $-0.02 | $0.14 | +800.0% | ✓ BEAT |
Q2 2025 | May 7, 2025 | $-0.05 | $-0.14 | -180.0% | ✗ MISS |
Q1 2025 | Feb 27, 2025 | $0.10 | $0.02 | -80.0% | ✗ MISS |
Q4 2024 | Nov 7, 2024 | $0.08 | $0.02 | -75.0% | ✗ MISS |
Q3 2024 | Aug 8, 2024 | $0.15 | $-0.01 | -103.6% | ✗ MISS |
Q2 2024 | May 9, 2024 | $0.18 | $-0.02 | -111.1% | ✗ MISS |
Q1 2024 | Feb 15, 2024 | $0.21 | $-0.01 | -104.8% | ✗ MISS |
Q4 2023 | Nov 9, 2023 | $0.16 | $0.09 | -43.8% | ✗ MISS |
Q3 2023 | Aug 8, 2023 | $0.25 | $0.31 | +24.0% | ✓ BEAT |
Q2 2023 | May 4, 2023 | $0.24 | $0.25 | +4.2% | ✓ BEAT |
Q1 2023 | Feb 16, 2023 | $0.27 | $0.27 | 0.0% | = MET |
Q4 2022 | Nov 3, 2022 | $0.27 | $0.28 | +3.7% | ✓ BEAT |
Q3 2022 | Aug 4, 2022 | $0.30 | $0.21 | -30.0% | ✗ MISS |
Q2 2022 | May 5, 2022 | $0.26 | $0.21 | -19.2% | ✗ MISS |
Q1 2022 | Feb 17, 2022 | $0.35 | $0.27 | -22.9% | ✗ MISS |
Q4 2021 | Nov 4, 2021 | $0.31 | $0.33 | +6.5% | ✓ BEAT |
Q3 2021 | Aug 5, 2021 | $0.23 | $0.34 | +47.8% | ✓ BEAT |
Latest News
Wells Fargo Maintains Equal-Weight on Ironwood Pharmaceuticals, Raises Price Target to $3
➖ NeutralBenzinga•Nov 11, 2025, 02:28 PM
Ironwood Pharmaceuticals shares are trading higher after the company reported better-than-expected Q3 financial results and raised its FY25 sales guidance above estimates.
📈 PositiveBenzinga•Nov 10, 2025, 02:16 PM
Ironwood Pharmaceuticals Raises FY2025 Sales Guidance from $260.000M-$290.000M to $290.000M-$310.000M vs $277.801M Est
📈 PositiveBenzinga•Nov 10, 2025, 12:25 PM
Ironwood Pharmaceuticals Q3 Adj. EPS $0.24 Beats $0.10 Estimate, Sales $122.060M Beat $74.701M Estimate
📈 PositiveBenzinga•Nov 10, 2025, 12:18 PM
Ironwood Pharmaceuticals shares are trading higher after the company announced that the FDA approved Linzess capsules for pediatric patients 7 years and older with irritable bowel syndrome with constipation.
📈 PositiveBenzinga•Nov 5, 2025, 05:34 PM
Ironwood wins FDA label expansion for bowel disease drug developed with AbbVie
📈 PositiveSeeking Alpha•Nov 5, 2025, 05:04 PM•Also:
FDA Approved Linzess Capsules For Pediatric Patients 7 Years And Older With Irritable Bowel Syndrome With Constipation; Linzess Recommended Dosage For Pediatric Patients 7 Years And Older With IBS-C Is 145 mcg Orally Once Daily
📈 PositiveBenzinga•Nov 5, 2025, 04:33 PM
Ironwood surges 28% as beneficiary of partner AbbVie's Linzess Q3 sales
📈 PositiveSeeking Alpha•Oct 31, 2025, 08:34 PM•Also:
Ironwood Pharmaceuticals hikes adjusted EBITDA guidance to greater than $105M, shares rise
📈 PositiveSeeking Alpha•Apr 25, 2025, 11:50 AM
Ironwood looks for strategic options after regulatory hurdle for lead drug
➖ NeutralSeeking Alpha•Apr 14, 2025, 12:58 PM
Frequently Asked Questions about IRWD
What is IRWD's current stock price?
Ironwood Pharmaceuticals, Inc. (IRWD) is currently trading at $3.13 per share. The stock has moved -3.99% today.
What is the analyst price target for IRWD?
The average analyst price target for IRWD is $3.80, based on 1 analyst.
What sector is Ironwood Pharmaceuticals, Inc. in?
Ironwood Pharmaceuticals, Inc. operates in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. The company is traded on the NASDAQ exchange.
What is IRWD's market cap?
Ironwood Pharmaceuticals, Inc. has a market capitalization of $0.51 billion, making it a small-cap company.
Does IRWD pay dividends?
No, Ironwood Pharmaceuticals, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorACB
Aurora Cannabis Inc.
$4.96
Mkt Cap: $0.3B
ALDX
Aldeyra Therapeutics, Inc.
$4.96
Mkt Cap: $0.3B
BIOA
BioAge Labs, Inc.
$13.39
Mkt Cap: $0.5B
CGC
Canopy Growth Corporation
$1.48
Mkt Cap: $0.4B
CLLS
Cellectis S.A.
$4.37
Mkt Cap: $0.4B
GNLX
Genelux Corporation
$4.20
Mkt Cap: $0.2B
LFCR
Lifecore Biomedical, Inc.
$8.04
Mkt Cap: $0.3B
NPCE
NeuroPace, Inc.
$16.59
Mkt Cap: $0.6B
SLN
Silence Therapeutics plc
$6.37
Mkt Cap: $0.3B
TKNO
Alpha Teknova, Inc.
$4.65
Mkt Cap: $0.2B
Explore stocks similar to IRWD for comparison